PhaseBio Pharmaceuticals Income Tax Provision

Income Tax Provision of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Income Tax Provision growth rates and interactive chart. The actual income tax expense for the applicable year.


Highlights and Quick Summary

  • Income Tax Provision for the quarter ending June 29, 2021 was $1.6 Million
  • Annual Income Tax Provision for 2019 was $-4.2 Million (a 23.53% increase from previous year)
  • Annual Income Tax Provision for 2018 was $-3.4 Million (a 6.25% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Income Tax Provision of PhaseBio Pharmaceuticals

Most recent Income Tax Provisionof PHAS including historical data for past 10 years.

Interactive Chart of Income Tax Provision of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Income Tax Provision for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $1.6
2019 $-4.2
2018 $-3.4
2017 $-3.2

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.